At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

The dispute centred around Gilead's triple-drug regimen Biktarvy, which is based on emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir. ViiV claimed the latter compound ...

Gilead Sciences’ long-acting drug to block HIV could end the AIDS epidemic worldwide. But access and funding remain big questions. © 2025 American City Business ...

I was genuinely, extremely nervous.” Nerves seem appropriate given the grand opulence of the Gilead wedding that was created for the former Mrs. Waterford’s second marriage to High Commander ...

Gilead Sciences’ long-acting drug to block HIV can end the AIDS epidemic worldwide. But accessibility is the question. © 2025 American City Business Journals. All ...